The initiative has been updated with a tiered structure and certification program.

StockWatch: Cosmo Surges 40% on Baldness Candidate’s Phase III Data
Cosmo Pharmaceuticals (SIX Swiss: COSM) found itself this past week in the enviable position of attracting welcome attention from investors and other market watchers after


